Clinical trials: Relapsed/Refractory Peripheral T Cell Lymphoma
Relapsed or Refractory Peripheral T-Cell Lymphoma
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL).
- Trial name
- PTCL (NCT02464228)
- Testing
- Tipifarnib
- Where
- 13 sites in United States, South Korea and 1 more
- Volunteers
- 65 people
- Sponsor
- Kura Oncology, Inc.
Relapsed and Refractory Peripheral T-cell Lymphoma
A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma
Peripheral T-cell lymphoma (PTCL) is a highly heterogeneous group of aggressive non-Hodgkin lymphoma (NHL) originating from mature thymus T cells.Mitoxantrone Hydrochloride Liposome Injection can accelerate the entry of…
- Trial name
- NCT05527275
- Testing
- Mitoxantrone liposome combine with Chidamide
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sun Yat-sen University
Mycosis Fungoides, Recurrent Anaplastic Large Cell Lymphoma
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma
This phase I trial studies the best dose and side effects of romidepsin when given in combination with ifosfamide, carboplatin, and etoposide in treating participants with peripheral T-cell lymphoma that has come back or does not…
- Conditions
- Mycosis Fungoides, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma
- Trial name
- NCT01590732
- Testing
- Carboplatin, Etoposide, Ifosfamide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Peripheral T-cell Lymphoma
Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma
This is a single center, open-label, phase I trial with a standard 3+3 dose escalation schema to identify the maximum tolerated dose (MTD) of selinexor when combined with ICE.
- Trial name
- NCT03212937
- Testing
- Selinexor, ICE Chemotherapy
- Where
- Singapore
- Volunteers
- 11 people
- Sponsor
- National Cancer Centre, Singapore
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
This phase I trial is studying how well ipilimumab works after allogeneic stem cell transplant in treating patients with persistent or progressive cancer.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00060372
- Testing
- ipilimumab, therapeutic allogeneic lymphocytes
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
- Trial name
- NCT06547528
- Testing
- ONO-4685
- Where
- 14 sites in Japan
- Volunteers
- 108 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Lymphoma, T-Cell
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
This study is a multicentric, open-label, randomized phase 3 trial. The study will be conducted in select countries in Europe and South Korea sponsored by LYSARC and in Japan sponsored by Celgene.
- Trial name
- NCT03703375
- Testing
- Azacitidine, Romidepsin, Gemcitabine
- Where
- 12 sites in Japan
- Volunteers
- 93 people
- Sponsor
- Celgene
Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
This phase I/II trial studies the side effects and the best dose of veliparib when given together with bendamustine hydrochloride and rituximab and to see how well they work in treating patients with lymphoma, multiple myeloma…
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult Solid Neoplasm, Anaplastic Large Cell Lymphoma
- Trial name
- NCT01326702
- Testing
- Bendamustine Hydrochloride, Pharmacological Study, Rituximab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Peripheral T-cell Lymphoma
Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma
This is a Phase I/II, open-label, single-arm study investigating the combination of chidamide and golidocitinib in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT06757387
- Testing
- chidamide and golidocitinib
- Volunteers
- 45 people
- Sponsor
- Peking University Cancer Hospital & Institute
T-cell Lymphoma
Study of Tazemetostat in Lymphoid Malignancies
Tazemetostat is an oral EZH2 inhibitor which has been FDA approved for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test…
- Trial name
- NCT05983965
- Testing
- Tazemetostat
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Alabama at Birmingham
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Classical Hodgkin Lymphoma
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
The goal of this clinical research study is to find the highest tolerable dose of TAK228 that can be given in combination with brentuximab vedotin in patients with lymphoma. The safety of this combination will also be studied.
- Conditions
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, CD30+ Peripheral T-cell Lymphoma
- Trial name
- NCT03205891
- Testing
- Brentuximab Vedotin, TAK228, Glucose Monitor
- Sponsor
- M.D. Anderson Cancer Center
T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory
Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma
The FIL_VERT study is a phase II, open label, multicenter clinical trial. The primary of objective of the Study is to evaluate the efficacy of Venetoclax ABT-199/GDC-0199) in terms of overall response rate (ORR) in patients with…
- Trial name
- NCT03552692
- Testing
- Venetoclax
- Where
- 13 sites in Italy
- Volunteers
- 22 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
This clinical trial studies massage therapy given by caregiver in treating quality of life of young patients undergoing treatment for cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Trial name
- NCT01053494
- Testing
- massage therapy, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Wake Forest University Health Sciences
Leukemia, Lymphoma
Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003294
- Testing
- filgrastim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roswell Park Cancer Institute
B-Cell Lymphoma
Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma
Clofarabine is a new chemotherapy drug which was FDA approved for the treatment of acute lymphocytic leukemia in children. This study is being done to see if Clofarabine works in adult patients with B-cell types of lymphoma.
- Trial name
- NCT00338494
- Testing
- Clofarabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Yale University
Extranodal NK/T-cell Lymphoma
GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of GPED (gemcitabine, pegaspargase, etoposide, and dexamethasone) regimen in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients
- Trial name
- NCT04917250
- Testing
- Gemcitabine, Pegaspargase, Etoposide
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Tongren Hospital
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
This phase II trial studies how well giving lenalidomide with or without rituximab works in treating patients with progressive or relapsed chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01419795
- Testing
- lenalidomide, rituximab, pharmacological study
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fred Hutchinson Cancer Center
T-cell Lymphoma
Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma
BCD (Bendamustine, carboplatin and dexamethasone)chemotherapy regimen is proposed as the salvage treatment for relapsed or refractory PTCLs in this study protocol, which would be expected to show more promising clinical outcomes…
- Trial name
- NCT02424045
- Testing
- BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Leukemia, Lymphoma
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 following bone marrow transplantation in treating patients who have…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003962
- Testing
- aldesleukin
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
This phase I trial studies the side effects and best dose of monoclonal antibody therapy before stem cell transplant in treating patients with relapsed or refractory lymphoid malignancies.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01678443
- Testing
- indium In 111 anti-CD45 monoclonal antibody BC8, yttrium Y 90 anti-CD45 monoclonal antibody BC8, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Fred Hutchinson Cancer Center